Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 12/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.66 |
| ▸ | CLK2 | P49760 | 3/20 | 0.65 |
| ▸ | CLK3 | P49761 | 3/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CCND3 | P30281 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637175 | 0.91 | ITK (0.66) | ITKMKNK1CLK2CLK3DYRK1A | |
| SCHEMBL18446988 | 0.87 | DYRK1A (0.65) | ITKCLK2CLK3DYRK1ACHEK1 | |
| SCHEMBL18448362 | 0.87 | DYRK1A (0.72) | ITKMKNK1CLK2CLK3DYRK1A | |
| SCHEMBL18444588 | 0.87 | DYRK1A (0.80) | MKNK1CLK2CLK3DYRK1AJAK2 | |
| SCHEMBL18446560 | 0.86 | CLK3 (0.82) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18441572 | 0.84 | DYRK1A (0.72) | MKNK1CLK2CLK3DYRK1AJAK2 | |
| SCHEMBL18446214 | 0.84 | ITK (0.63) | ITKCLK2CLK3DYRK1ACHEK1 | |
| SCHEMBL18446659 | 0.83 | CLK3 (0.75) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18447292 | 0.83 | CLK3 (0.66) | ITKCLK2CLK3DYRK1ACHEK1 | |
| SCHEMBL18452327 | 0.83 | ITK (0.54) | ITKMKNK1CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | claimed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| WO-2017023986-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | ITK 1501/4885MKNK1 48/4885CLK2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.